10.75
0.24 (2.28%)
| Previous Close | 10.51 |
| Open | 10.64 |
| Volume | 1,857,906 |
| Avg. Volume (3M) | 2,340,827 |
| Market Cap | 1,407,089,024 |
| Price / Earnings (TTM) | 153.57 |
| Price / Earnings (Forward) | 52.36 |
| Price / Sales | 5.50 |
| Price / Book | 2.13 |
| 52 Weeks Range | |
| Earnings Date | 1 Aug 2024 - 5 Aug 2024 |
| Profit Margin | 6.88% |
| Operating Margin (TTM) | 10.03% |
| Diluted EPS (TTM) | 0.130 |
| Quarterly Revenue Growth (YOY) | 22.50% |
| Quarterly Earnings Growth (YOY) | 231.90% |
| Total Debt/Equity (MRQ) | 39.71% |
| Current Ratio (MRQ) | 14.18 |
| Operating Cash Flow (TTM) | 38.93 M |
| Levered Free Cash Flow (TTM) | 24.81 M |
| Return on Assets (TTM) | -0.79% |
| Return on Equity (TTM) | 2.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Dynavax Technologies Corporatio | Bullish | Bullish |
Stockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.75 |
|
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Insiders | 0.34% |
| % Held by Institutions | 103.81% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (HC Wainwright & Co., 169.77%) | Buy |
| Median | 22.00 (104.65%) | |
| Low | 15.00 (Goldman Sachs, 39.54%) | Hold |
| Average | 22.00 (104.65%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 10.73 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 15 Oct 2024 | 29.00 (169.77%) | Buy | 10.76 |
| Goldman Sachs | 08 Aug 2024 | 15.00 (39.53%) | Hold | 10.70 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 Aug 2024 | Announcement | Dynavax Reports Second Quarter 2024 Financial Results and Provides Business Updates |
| 23 Jul 2024 | Announcement | Dynavax to Report Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |